Brodsky & Smith investigates Apogee, Roku, TruBridge, and Organon boards over merger deals

Corporate Action
โดย GlobeNewswire·Read original
Summary · why it matters

Brodsky & Smith is investigating the boards of Apogee Therapeutics, Roku, TruBridge, and Organon over potential fiduciary duty breaches in their respective merger agreements. Apogee is being acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion in total equity. Roku is being acquired by Fox Corporation for $160.00 per share in a mix of cash and FOX Class A common stock, with an enterprise value of about $22 billion. TruBridge is being acquired by Inventurus Knowledge Solutions for $26.25 per share in cash. Organon is being acquired by Sun Pharmaceutical Industries for $14.00 per share in an all-cash deal with an enterprise valuation of $11.75 billion. The investigations focus on whether the boards failed to conduct a fair process and whether the deal consideration provides fair value to shareholders.

Impact on stocks 5

Biotech & Genomic Medicine▼ · 2 stocks
Health Care▼ · 1 stocks
Organon & Co
OGN
▼ NegativeRegulationrelevance

Investigation into board's fiduciary duties could delay or reduce deal consideration for Organon shareholders.

Communication Services▼ · 1 stocks
Roku Inc
ROKU
▼ NegativeRegulationrelevance

Investigation into board's fiduciary duties could delay or reduce deal consideration for Roku shareholders.

Cloud & Digital Infrastructure▼ · 1 stocks
TruBridge Inc.
TBRG
▼ NegativeRegulationrelevance

Investigation into board's fiduciary duties could delay or reduce deal consideration for TruBridge shareholders.

© 2026 MarketDXNews